← Back to Clinical Trials
Recruiting NCT07033052

NCT07033052 Developing Resilience and Anxiety Management Through the Arts

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07033052
Status Recruiting
Phase
Sponsor Case Western Reserve University
Condition Anxiety
Study Type INTERVENTIONAL
Enrollment 110 participants
Start Date 2025-04-15
Primary Completion 2027-07-01

Eligibility & Interventions

Sex All sexes
Min Age 8 Years
Max Age 17 Years
Study Type INTERVENTIONAL
Interventions
Improvisation + WellnessImprovisationSocial Craft

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 110 participants in total. It began in 2025-04-15 with a primary completion date of 2027-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The Developing Resilience and Anxiety Management Through the Arts (DRAMA) Study examines the degree to which the arts can help to address stress, anxiety, and sad mood in children and adolescents. The researchers will pair theatrical improvisation exercises with cognitive-behavioral therapy (CBT) techniques versus improvisation exercises alone versus a social craft group on reducing elevated levels of anxiety and depression.

Eligibility Criteria

Inclusion Criteria: * Between 8 and 17 years of age * Individuals must have parental/guardian consent * Elevated levels of anxiety or depression based on 1. Screen for Child Anxiety Related Disorders (SCARED) score of 15 or higher, or; 2. Revised Children's Anxiety and Depression Scale (RCADS) Depression T score of 65 or higher, or; 3. Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) clinician severity rating of 3 on any anxiety disorder or on a mood-related disorder Exclusion Criteria: * Diagnosed with Conduct Disorder or with behavioral symptoms that would make it difficult for the child/adolescent to participate in the group or comply with directions given by the group leader (such as difficulty following instructions, difficulty staying in one's seat, defiance of adults, harming animals or people, threatening others, getting into physical fights, hyperactivity, impulsivity, difficulty waiting for one's turn, etc.) * Autism or developmental delays * Psychotic symptoms or active suicidality * Active Eating Disorders that raise concerns about morbidity and therefore need to be addressed in an intervention and actively monitored * Unsteady dosage or recently or impending changes to psychotropic medication(s) * Non-English-speaking individuals * Wards of the State

Contact & Investigator

Central Contact

Amy Przeworski, PhD

✉ axp335@case.edu

📞 216-368-5021

Principal Investigator

Amy Przeworski, PhD

PRINCIPAL INVESTIGATOR

Case Western Reserve University

Frequently Asked Questions

Who can join the NCT07033052 clinical trial?

This trial is open to participants of all sexes, aged 8 Years or older, up to 17 Years, studying Anxiety. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07033052 currently recruiting?

Yes, NCT07033052 is actively recruiting participants. Contact the research team at axp335@case.edu for enrollment information.

Where is the NCT07033052 trial being conducted?

This trial is being conducted at Cleveland, United States.

Who is sponsoring the NCT07033052 clinical trial?

NCT07033052 is sponsored by Case Western Reserve University. The principal investigator is Amy Przeworski, PhD at Case Western Reserve University. The trial plans to enroll 110 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology